Abbott trims profit forecast

The company now expects adjusted profit per share between $5.38 and $5.58, down from its previous range of $5.55 to $5.80.

Despite the guidance cut, Abbott's first-quarter revenue topped analyst estimates, driven by strong sales in its medical device segment.

Executives noted that a moderate flu season resulted in lower demand for diagnostic tests, impacting the nutrition business.

The integration of Exact Sciences is expected to cause a $0.20 dilution to earnings per share in 2026.